Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality

Dean T Eurich, Ross T Tsuyuki, Sumit R Majumdar, Finlay A McAlister, Richard Lewanczuk, Marcelo C Shibata, Jeffrey A Johnson, Dean T Eurich, Ross T Tsuyuki, Sumit R Majumdar, Finlay A McAlister, Richard Lewanczuk, Marcelo C Shibata, Jeffrey A Johnson

Abstract

Objective: Metformin has had a 'black box' contraindication in diabetic patients with heart failure (HF), but many believe it to be the treatment of choice in this setting. Therefore, we attempted to conduct a pilot study to evaluate the feasibility of undertaking a large randomized controlled trial with clinical endpoints.

Study design: The pilot study was a randomized double blinded placebo controlled trial. Patients with HF and type 2 diabetes were screened in hospitals and HF clinics in Edmonton, Alberta, Canada (population ~1 million). Major exclusion criteria included the current use of insulin or high dose metformin, decreased renal function, or a glycosylated hemoglobin <7%. Patients were to be randomized to 1500 mg of metformin daily or matching placebo and followed for 6 months for a variety of functional outcomes, as well as clinical events.

Results: Fifty-eight patients were screened over a six month period and all were excluded. Because of futility with respect to enrollment, the pilot study was abandoned. The mean age of screened patients was 77 (SD 9) years and 57% were male. The main reasons for exclusion were: use of insulin therapy (n = 23; 40%), glycosylated hemoglobin <7% (n = 17; 29%) and current use of high dose metformin (n = 12; 21%). Overall, contraindicated metformin therapy was the most commonly prescribed oral antihyperglycemic agent (n = 27; 51%). On average, patients were receiving 1,706 mg (SD 488 mg) of metformin daily and 12 (44%) used only metformin.

Conclusion: Despite uncertainty in the scientific literature, there does not appear to be clinical uncertainty with regards to the safety or effectiveness of metformin in HF making a definitive randomized trial virtually impossible.

Trial registration: ClinicalTrials.gov Identifier: NCT00325910.

Figures

Figure 1
Figure 1
Reason for study exclusion.

References

    1. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541–549. doi: 10.1056/NEJM199508313330902.
    1. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with metformin use compared to sulfonylurea monotherapy in type 2 diabetes mellitus. Diabetes Care. 2002;25:2244–2248. doi: 10.2337/diacare.25.12.2244.
    1. UK Prospective Diabetes Study group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865. doi: 10.1016/S0140-6736(98)07037-8.
    1. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure. Diabetes Care. 2005;28:2345–2351. doi: 10.2337/diacare.28.10.2345.
    1. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168–174. doi: 10.1016/j.ahj.2004.07.005.
    1. Canadian Pharmaceutical Association Compendium of pharmaceuticals and specialties (Canada) 2004.
    1. Inzucchi SE. Metformin and heart failure: innocent until proven guilty. Diabetes Care. 2005;28:2585–2587. doi: 10.2337/diacare.28.10.2585.
    1. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care. 2007;30:e129. doi: 10.2337/dc07-1686.
    1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879–1884. doi: 10.2337/diacare.27.8.1879.
    1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34. doi: 10.1016/0002-9149(74)90089-7.
    1. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded. Diabet Med. 1999;16:692–696. doi: 10.1046/j.1464-5491.1999.00115.x.
    1. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81–85. doi: 10.1001/jama.290.1.81.
    1. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27:1791–1793. doi: 10.2337/diacare.27.7.1791.
    1. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22:925–927. doi: 10.2337/diacare.22.6.925.
    1. Fantus IG. Metformin's contraindications: needed for now. Canadian Medical Association Journal. 2005;173:505–507. doi: 10.1503/cmaj.050401.
    1. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163:2594–2602. doi: 10.1001/archinte.163.21.2594.
    1. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–590. doi: 10.1161/01.CIR.0000154542.13412.B1.
    1. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, Rothman R. Frequency of inappropriate metformin prescriptions. JAMA. 2002;287:2504–2505. doi: 10.1001/jama.287.19.2504-a.
    1. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ. 2005;173:502–504.
    1. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with Type 2 diabetes – a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18:483–488. doi: 10.1046/j.1464-5491.2001.00509.x.
    1. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20:489–503. doi: 10.2165/00002018-199920060-00003.
    1. Levenson D. Patients with both diabetes and heart failure often treated with medications government considers unsafe. Report on Medical Guidelines & Outcomes Research. 2003;14:1–7.
    1. Rachmani R. Metformin in patients with type 2 diabetes mellitus: Reconsideration of traditional contraindications. European Journal of Internal Medicine. 2002;13:428–433. doi: 10.1016/S0953-6205(02)00131-0.
    1. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925–928. doi: 10.2337/diacare.20.6.925.
    1. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497. doi: 10.1136/bmj.39314.620174.80.
    1. Sackett DL. Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle. CMAJ. 2000;162:1311–1314.
    1. Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, Maksymowych WP, Steiner IP, Harley CH, Wizba BJ, Hanley DA, Blitz A, Russell AS. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med. 2004;141:366–373.
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2003;27:s1–s152.
    1. Tsuyuki RT, Fradette M, Johnson JA, Bungard TJ, Eurich DT, Ashton T, Gordon W, Ikuta R, Komder J, Mackav E, Manyari D, O"Reilly K, Semchuk W. A multicenter disease management program for hospitalized patients with heart failure. J Card Fail. 2004;10:473–480. doi: 10.1016/j.cardfail.2004.02.005.
    1. Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z. Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. BMC Health Serv Res. 2006;6:159. doi: 10.1186/1472-6963-6-159.
    1. Besner HK, Feemster AA, Bongiorno RA. Evaluation of metformin use in hospitalized patients. Ashp Midyear Clinical Meeting. 2004;39:243E.
    1. Khandwala HM. The prevalence of contraindications to the use of metformin. Can J Diabetes. 2004;28:380–384.
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committe Canadian Diabetes Association 2008 clincal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32:S1–S201.
    1. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, Colthart IR, Ross S, Shepherd SM, Russell D. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess. 1999;3:1–143.
    1. Taylor KM, Margolese RG, Soskolne CL. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med. 1984;310:1363–1367.
    1. Benson AB, III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991;9:2067–2075.
    1. Tognoni G, Alli C, Avanzini F, Bettelli G, Colombo F, Corso R, Marchiolo R, Zussino A. Randomised clinical trials in general practice: lessons from a failure. BMJ. 1991;303:969–971.
    1. Majumdar SR, McAlister FA, Furberg CD. From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol. 2004;43:1738–1742. doi: 10.1016/j.jacc.2003.12.043.
    1. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614–1619. doi: 10.2337/diacare.24.9.1614.
    1. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75. doi: 10.1093/eurheartj/ehi555.
    1. Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Archives of Internal Medicine. 2004;164:2273–2279. doi: 10.1001/archinte.164.20.2273.
    1. Laupacis A, Mamdani M. Observational studies of treatment effectiveness: some cautions. Ann Intern Med. 2004;140:923–924.
    1. D'Agostino RB, Jr, D'Agostino RB., Sr Estimating treatment effects using observational data. JAMA. 2007;297:314–316. doi: 10.1001/jama.297.3.314.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever